Sort
51,570 grants matching “autoimmune disease”
Consortium for Identification of Environmental Triggers*
$1,000,000Medical College Of Georgia (Mcg) · U01 · FY2004 · DK
A Multi-Center Group to Study Acute Liver Failure
$1,000,000William M Lee · Ut Southwestern Medical Center · U01 · FY2019 · DK
Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy
$1,000,000Hua Wu · Sab Biotherapeutics, Inc. · R44 · FY2019 · AI
Type 1 Diabetes triggers: diet modification in neonates
$1,000,000Diabetes Research Institute · U01 · FY2003 · DK
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2022 · CA
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
$1,000,000Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2023 · AI
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
$1,000,000David H Wagner · Op-T-Mune, Inc. · R42 · FY2019 · AI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
$1,000,000Neil A Fanger · Virtici, Llc · R44 · FY2017 · AI
Environmental Causes of Type 1 Diabetes
$1,000,000University Of Colorado Denver · U01 · FY2003 · DK
Exposure to PFNA and other PFAS in drinking water and associations with health-related outcomes in Gloucester County NJ
$1,000,000Robert John Laumbach · Rbhs-School Of Public Health · U01 · FY2019 · TS
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2021 · CA
Production Technology for Recombinant Intravenous Immunoglobulin
$1,000,000David Scott Johnson · Gigagen, Inc. · R44 · FY2017 · AI
Exposure to PFNA and other PFAS in drinking water and associations with health-related outcomes in Gloucester County NJ
$1,000,000Robert John Laumbach · Rbhs-School Of Public Health · U01 · FY2021 · TS
RAISE: A Phase Separation Model for Transcriptional Control in Mammals
$1,000,000Arup K Chakraborty · Massachusetts Institute Of Technology · · FY2017 · MPS
Development of a novel accurate therapy for multiple sclerosis
$1,000,000Gaddiel Galarza-Munoz · Autoimmunity Biologic Solutions, Inc. · R42 · FY2022 · AI
Consortium for Identification of Environmental Triggers*
$1,000,000Medical College Of Georgia (Mcg) · U01 · FY2003 · DK
Diabetes Evaluation in Washington (DEW-IT) Clinical Cen*
$1,000,000Pacific Northwest Research Institute · U01 · FY2003 · DK
Advanced PML antiviral
$1,000,000Milton H. Werner · Inhibikase Therapeutics · R44 · FY2017 · AI
A Multi-Center Group to Study Acute Liver Failure
$1,000,000William M Lee · Ut Southwestern Medical Center · U01 · FY2018 · DK
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
$1,000,000Kenneth Schultz · Trethera Corporation · R44 · FY2025 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$1,000,000Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2019 · AI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes
$1,000,000Christian Furlan Freguia · Rise Therapeutics, Llc · R44 · FY2023 · DK
Delivery system development for a reservoir targeted Lyme disease vaccine
$1,000,000Linden T Hu · Foodsource Lure Corporation · R42 · FY2012 · AI
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
A 3D Tissue Map of the Human Lymphatic System
$1,000,000Mark A Atkinson · University Of Florida · U54 · FY2019 · AI